AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
Amgen presented new Phase 3 clinical trial data at the American Diabetes Association sessions showing that Repatha reduces the risk of major cardiovascular events in high-risk diabetes patients. The study indicates a 29% reduction in heart attack and stroke risk when the drug is added to standard cholesterol-lowering therapies.
Why it matters
These findings offer significant clinical implications for managing cardiovascular health in patients with diabetes, potentially changing standard treatment protocols.
VESALIUS-CV Subgroup Results Show Repatha ® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk Diabetes
The content is a corporate press release summarizing clinical trial results, which is factual and data-driven.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in